IM19抗CD19 CAR-T细胞治疗难治性系统性红斑狼疮的异质性反应:开放标签初步研究及小型综述
本研究为开放标签单臂临床试验,评估IM19自体抗CD19 CAR-T细胞治疗6例难治性系统性红斑狼疮(SLE)伴肾脏受累患者的安全性和疗效。治疗后SLEDAI-2K评分从基线12降至第90天4,第180天稳定于5;肾脏反应异质,2例完全缓解、2例部分缓解、2例无反应。小型综述显示CAR-T治疗狼疮肾炎的肾脏完全缓解率为72.4%,高龄与反应欠佳相关。
要点
- IM19 CAR-T治疗难治性SLE耐受良好,4例发生轻度细胞因子释放综合征。
- 肾脏反应异质:6例中2例完全缓解、2例部分缓解、2例无反应。
- 重复肾活检显示无B细胞浸润,但以慢性改变和足细胞病为主。
核心结论
- IM19 CAR-T细胞治疗在难治性SLE中显示良好安全性和有临床意义的全身改善。
- 狼疮肾炎对CAR-T治疗的反应存在异质性。
- 慢性肾脏表现、足细胞病和年龄增长与治疗反应欠佳相关。
研究设计与样本
- 开放标签、单臂临床试验,纳入6例难治性SLE伴肾脏受累患者。
- IM19为自体抗CD19 CAR-T细胞,淋巴细胞清除后输注。
- 第180天重复肾活检,CAR-T输注前及第180天对外周血单个核细胞进行单细胞RNA测序。
- 在PubMed数据库检索CAR-T细胞治疗狼疮肾炎疗效的文献进行小型综述。
主要发现
- IM19治疗耐受良好,4例患者发生轻度细胞因子释放综合征。
- SLEDAI-2K中位评分从基线12(范围10-24)降至第90天4(范围2-8),第180天稳定于5(范围2-6)。
- 肾脏反应异质:2例完全缓解、2例部分缓解、2例无反应。
- 重复肾活检显示无B细胞浸润,但以慢性改变和足细胞病为主。
- 单细胞分析证实3/6例患者出现B细胞重建。
关键数值与推荐
- 小型综述显示CAR-T治疗狼疮肾炎的肾脏完全缓解率为72.4%。
- 高龄与CAR-T治疗反应欠佳相关。
临床怎么用
- IM19 CAR-T可用于难治性SLE伴肾脏受累患者,需关注肾脏反应的异质性。
- 治疗前应评估慢性肾脏改变、足细胞病和年龄因素对疗效的潜在影响。
局限性
- 开放标签、单臂设计,样本量小(6例),缺乏对照组。
- 随访至第180天,长期疗效和安全性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to evaluate the efficacy and safety of IM19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell, in patients with refractory systemic lupus erythematosus (SLE), with a particular focus on lupus nephritis (LN). METHODS: This is an open-label, single-arm clinical trial. IM19 was administered following lymphodepletion. Repeated renal biopsies were performed at day 180. Single-cell RNA sequencing on peripheral blood mononuclear cells was performed pre- and 180-day post-CAR-T infusion. A literature search on the efficacy of CAR T-cell therapy in LN in PubMed database was conducted. RESULTS: Six patients with refractory SLE and renal involvement were enrolled. IM19 therapy was well tolerant, with mild cytokine release syndrome occurring in 4 patients. The median Systemic Lupus Erythematosus Disease Activity Index-2000 score decreased from 12 (range, 10-24) to 4 (range, 2-8) at day 90, and remained stable at 5 (range, 2-6) at day 180. The renal responses were heterogeneous with 2 complete responders, 2 partial responders, and 2 nonresponders. Repeated renal biopsies showed no B-cell infiltration, but dominant chronic changes and podocytopathies post-CAR-T therapy. A mini-review demonstrated that the renal complete response rate of CAR-T therapy was 72.4%, and advanced age was associated with suboptimal response. Single-cell analysis confirmed B-cell reconstitution in 3/6 patients. CONCLUSIONS: IM19 CAR T-cell therapy demonstrated a favourable safety profile and clinically meaningful systemic improvement. Responses to CAR-T therapy in LN were variable. Chronic renal manifestations, podocytopathy, and ageing were associated with suboptimal therapeutic outcome.
引用
- Zhao J, Zhang X, Zhang Y, et al. Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review. Ann Rheum Dis. 2026. PMID: 41644365. doi:10.1016/j.ard.2025.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。